Upon completion of the 4-week Ang II stimulation, in marked agreement with the results from the Apoe−/−IKKε−/− mice, amlexanox administration dramatically reduced AAA incidence amd mortality in mice (Figure 7(a)). This evidence concerns the gene APOE and triple-A syndrome.